Lantheus (NASDAQ:LNTH) Upgraded at Wall Street Zen

Lantheus (NASDAQ:LNTH) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

LNTH has been the subject of several other reports. Truist Financial increased their price objective on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th. Mizuho increased their price target on Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Finally, JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average target price of $86.14.

Lantheus Price Performance

Shares of LNTH stock opened at $74.47 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. The company has a market capitalization of $4.85 billion, a PE ratio of 22.10 and a beta of -0.11. The firm’s 50-day moving average is $72.49 and its two-hundred day moving average is $63.27. Lantheus has a 12 month low of $47.25 and a 12 month high of $108.91.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts predict that Lantheus will post 6.01 earnings per share for the current year.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently bought and sold shares of LNTH. Legal & General Group Plc raised its position in Lantheus by 1.1% in the 2nd quarter. Legal & General Group Plc now owns 152,466 shares of the medical equipment provider’s stock valued at $12,481,000 after purchasing an additional 1,604 shares in the last quarter. Rhumbline Advisers grew its position in shares of Lantheus by 1.9% during the second quarter. Rhumbline Advisers now owns 220,416 shares of the medical equipment provider’s stock worth $18,043,000 after buying an additional 4,120 shares in the last quarter. Prudential Financial Inc. increased its stake in shares of Lantheus by 49.4% during the second quarter. Prudential Financial Inc. now owns 10,471 shares of the medical equipment provider’s stock worth $825,000 after buying an additional 3,460 shares during the period. XTX Topco Ltd increased its stake in shares of Lantheus by 91.8% during the second quarter. XTX Topco Ltd now owns 9,577 shares of the medical equipment provider’s stock worth $784,000 after buying an additional 4,584 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Lantheus in the second quarter valued at approximately $26,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.